title: Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
abstract: Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative responses were detected at > or =2 time points in 44%-56% of vaccinees and none of the placebo recipients. A cytotoxic T lymphocyte response on at least 1 occasion was detected in 62.5% of infants in cohort 1 (10(6.08) median tissue culture dose [TCID(50)] vaccine formulation) and 44% of infants in cohort 2 (10(6.33) TCID(50) vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic.
authors.affiliation: Sinai Children's Hospital and Rosalind Franklin University of Medicine and Science, North Chicago, IL 60608, USA. johda@sinai.org
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Johnson
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: McFarland
authors.forename: Petronella
authors.initials: P
authors.lastname: Muresan
authors.forename: Terence
authors.initials: T
authors.lastname: Fenton
authors.forename: James
authors.initials: J
authors.lastname: McNamara
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Read
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hawkins
authors.forename: Pamela L
authors.initials: PL
authors.lastname: Bouquin
authors.forename: Scharla G
authors.initials: SG
authors.lastname: Estep
authors.forename: Georgia D
authors.initials: GD
authors.lastname: Tomaras
authors.forename: Carol A
authors.initials: CA
authors.lastname: Vincent
authors.forename: Mobeen
authors.initials: M
authors.lastname: Rathore
authors.forename: Ann J
authors.initials: AJ
authors.lastname: Melvin
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gurunathan
authors.forename: John
authors.initials: J
authors.lastname: Lambert
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology*; D005260:Female; D015483:HIV Antibodies / Q000032:analysis / Q000097:blood; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007223:Infant; D007231:Infant, Newborn; D008213:Lymphocyte Activation; D009092:Mucous Membrane / Q000276:immunology; D012463:Saliva / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; C468115:ALVAC-HIV-1 vCP205; D015483:HIV Antibodies; D007071:Immunoglobulin A, Secretory; D014614:Vaccines, Synthetic